Compare MEOH & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEOH | IDYA |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.9B |
| IPO Year | 1995 | 2019 |
| Metric | MEOH | IDYA |
|---|---|---|
| Price | $52.66 | $34.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $47.75 | ★ $51.21 |
| AVG Volume (30 Days) | 757.5K | ★ 783.9K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $19.36 | N/A |
| Revenue Next Year | $1.17 | $213.03 |
| P/E Ratio | $16.44 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $25.46 | $13.45 |
| 52 Week High | $57.93 | $39.28 |
| Indicator | MEOH | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 55.27 |
| Support Level | $46.36 | $32.85 |
| Resistance Level | N/A | $36.38 |
| Average True Range (ATR) | 2.61 | 1.27 |
| MACD | 0.01 | 0.35 |
| Stochastic Oscillator | 47.76 | 71.26 |
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.